Orthofix Medical Inc. (OFIX) Spending and interest coverage
- R&D / revenue · 12 months: Value 7.37%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 3.44%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 7.37% | Research and development expense / revenue. Period ending 2026-06-30. $61.41M ÷ $833.19M × 100 ≈ 7.37% |
| Stock-based compensation / revenue · 12 months | 3.44% | Share-based compensation / revenue. Period ending 2026-06-30. $28.66M ÷ $833.19M × 100 ≈ 3.44% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 61.41M USD | Research and Development Expense |
| Revenue | 833.19M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 28.66M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -39.12M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $61.41M | $833.19M | $28.66M | $-39.12M | (m) | 7.37% | 3.44% | (m) | (m) |
| 2026-03-31 | $61.40M | $825.37M | $28.75M | $-46.99M | (m) | 7.44% | 3.48% | (m) | (m) |
| 2025-12-31 | $65.85M | $822.31M | $28.69M | $-81.43M | (m) | 8.01% | 3.49% | (m) | (m) |
| 2025-09-30 | $69.28M | $818.06M | $28.64M | $-93.40M | (m) | 8.47% | 3.50% | (m) | (m) |
| 2025-06-30 | $71.80M | $809.03M | $27.99M | $-95.25M | (m) | 8.88% | 3.46% | (m) | (m) |
| 2025-03-31 | $73.92M | $804.53M | $30.12M | $-104.16M | (m) | 9.19% | 3.74% | (m) | (m) |
| 2024-12-31 | $73.64M | $799.49M | $32.45M | $-84.62M | (m) | 9.21% | 4.06% | (m) | (m) |
| 2024-09-30 | $73.78M | $784.25M | $28.46M | $-91.46M | (m) | 9.41% | 3.63% | (m) | (m) |
| 2024-06-30 | $75.04M | $771.65M | $28.20M | $-97.01M | (m) | 9.72% | 3.65% | (m) | (m) |
| 2024-03-31 | $76.42M | $760.04M | $31.49M | $-108.73M | (m) | 10.05% | 4.14% | (m) | (m) |
| 2023-12-31 | $80.23M | $746.64M | $35.71M | $-139.11M | (m) | 10.75% | 4.78% | (m) | (m) |
| 2023-09-30 | $74.44M | $668.46M | $37.46M | $-131.84M | (m) | 11.14% | 5.60% | (m) | (m) |
| 2023-06-30 | $67.83M | $598.45M | $35.92M | $-113.18M | (m) | 11.33% | 6.00% | (m) | (m) |
| 2023-03-31 | $61.16M | $529.50M | $27.13M | $-69.90M | (m) | 11.55% | 5.12% | (m) | (m) |
| 2022-12-31 | $49.06M | $460.71M | $18.44M | $-13.27M | (m) | 10.65% | 4.00% | (m) | (m) |
| 2022-09-30 | $49.16M | $463.55M | $17.48M | $-11.58M | (m) | 10.60% | 3.77% | (m) | (m) |
| 2022-06-30 | $49.57M | $461.98M | $16.60M | $-6.10M | (m) | 10.73% | 3.59% | (m) | (m) |
| 2022-03-31 | $49.94M | $465.30M | $16.04M | $-8.48M | (m) | 10.73% | 3.45% | (m) | (m) |
| 2021-12-31 | $49.62M | $464.48M | $15.43M | $-8.31M | (m) | 10.68% | 3.32% | (m) | (m) |
| 2021-09-30 | $46.74M | $457.03M | $15.28M | $4.74M | (m) | 10.23% | 3.34% | (m) | (m) |
| 2021-06-30 | $44.34M | $455.59M | $15.28M | $9.23M | (m) | 9.73% | 3.35% | (m) | (m) |
| 2021-03-31 | $39.99M | $407.33M | $16.07M | $-16.04M | (m) | 9.82% | 3.94% | (m) | (m) |
| 2020-12-31 | $39.06M | $406.56M | $16.21M | $-6.27M | (m) | 9.61% | 3.99% | (m) | (m) |
| 2020-09-30 | $37.14M | $410.44M | $16.56M | $-5.88M | (m) | 9.05% | 4.03% | (m) | (m) |
| 2020-06-30 | $35.16M | $412.95M | $18.56M | $-28.93M | (m) | 8.51% | 4.50% | (m) | (m) |
| 2020-03-31 | $35.37M | $455.67M | $19.71M | $-7.48M | (m) | 7.76% | 4.33% | (m) | (m) |
| 2019-12-31 | $34.64M | $459.95M | $21.54M | $-18.78M | (m) | 7.53% | 4.68% | (m) | (m) |
| 2019-09-30 | $34.98M | $459.54M | $21.92M | $-10.48M | (m) | 7.61% | 4.77% | (m) | (m) |
| 2019-06-30 | $36.60M | $457.75M | $21.33M | $12.31M | (m) | 8.00% | 4.66% | (m) | (m) |
| 2019-03-31 | $35.51M | $453.44M | $20.70M | $17.78M | (m) | 7.83% | 4.56% | (m) | (m) |
| 2018-12-31 | $33.22M | $453.04M | $18.93M | $30.09M | (m) | 7.33% | 4.18% | (m) | (m) |
| 2018-09-30 | $32.88M | $448.86M | $17.82M | $35.55M | (m) | 7.33% | 3.97% | (m) | (m) |
| 2018-06-30 | $30.22M | $442.40M | $16.20M | $41.79M | (m) | 6.83% | 3.66% | (m) | (m) |
| 2018-03-31 | $29.21M | $439.79M | $13.66M | $42.77M | (m) | 6.64% | 3.11% | (m) | (m) |
| 2017-12-31 | $29.70M | $433.82M | $12.56M | $40.81M | (m) | 6.85% | 2.89% | (m) | (m) |
| 2017-09-30 | $28.75M | $425.46M | $12.94M | $30.37M | (m) | 6.76% | 3.04% | (m) | (m) |
| 2017-06-30 | $28.68M | $418.71M | $17.45M | $30.60M | (m) | 6.85% | 4.17% | (m) | (m) |
| 2017-03-31 | $28.59M | $413.85M | $16.68M | $19.91M | (m) | 6.91% | 4.03% | (m) | (m) |
| 2016-12-31 | $28.80M | $409.79M | $15.97M | $21.07M | (m) | 7.03% | 3.90% | (m) | (m) |
| 2016-09-30 | $28.86M | $405.87M | (m) | $21.03M | (m) | 7.11% | (m) | (m) | (m) |
| 2016-06-30 | $28.52M | $408.53M | (m) | $16.01M | (m) | 6.98% | (m) | (m) | (m) |
| 2016-03-31 | $28.18M | $405.41M | (m) | $23.57M | (m) | 6.95% | (m) | (m) | (m) |
| 2015-12-31 | $26.39M | $396.49M | $7.21M | $9.26M | (m) | 6.66% | 1.82% | (m) | (m) |
| 2015-09-30 | $25.00M | $392.15M | (m) | $5.83M | (m) | 6.37% | (m) | (m) | (m) |
| 2015-06-30 | $25.04M | $391.99M | (m) | $8.20M | (m) | 6.39% | (m) | (m) | (m) |
| 2015-03-31 | $24.91M | $392.02M | (m) | $9.97M | $1.59M | 6.35% | (m) | 6.28× | Reported |
| 2014-12-31 | $24.99M | $402.28M | $5.72M | $17.14M | $1.78M | 6.21% | 1.42% | 9.60× | Reported |
| 2014-09-30 | $24.93M | $407.82M | $5.66M | $3.10M | $1.65M | 6.11% | 1.39% | 1.89× | Reported |
| 2014-06-30 | $24.72M | $398.69M | $5.20M | $-17.50M | $1.79M | 6.20% | 1.31% | -9.78× | Reported |
| 2014-03-31 | $26.97M | $398.50M | $5.79M | $-10.71M | $1.85M | 6.77% | 1.45% | -5.79× | Reported |
| 2013-12-31 | $26.77M | $400.53M | $6.27M | $-5.09M | $1.93M | 6.68% | 1.56% | -2.64× | Reported |
| 2013-09-30 | $26.07M | $411.76M | $6.18M | $26.90M | $2.38M | 6.33% | 1.50% | 11.31× | Reported |
| 2013-06-30 | $26.57M | $426.88M | $7.00M | $61.31M | $2.29M | 6.22% | 1.64% | 26.81× | Reported |
| 2013-03-31 | $26.93M | $446.53M | $6.77M | $70.60M | $2.92M | 6.03% | 1.52% | 24.21× | Reported |
| 2012-12-31 | $28.58M | $462.32M | $6.30M | $89.01M | $4.58M | 6.18% | 1.36% | 19.45× | Reported |
| 2012-09-30 | $30.65M | $582.24M | $6.39M | $81.55M | $6.86M | 5.26% | 1.10% | 11.89× | Reported |
| 2012-06-30 | $29.78M | $584.79M | $5.65M | $83.62M | $8.66M | 5.09% | 0.97% | 9.65× | Reported |
| 2012-03-31 | $26.84M | $582.96M | $6.62M | $80.62M | $9.60M | 4.60% | 1.14% | 8.40× | Reported |
| 2011-12-31 | $25.15M | $578.99M | $6.65M | $32.52M | $9.79M | 4.34% | 1.15% | 3.32× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | $564.71M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $30.35M | $564.37M | $8.14M | $88.99M | $17.23M | 5.38% | 1.44% | 5.17× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $31.46M | $545.63M | $10.75M | $63.88M | $24.82M | 5.77% | 1.97% | 2.57× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |